Get access

Inositol for depressive disorders

  • Review
  • Intervention

Authors


Abstract

Background

There are a number of effective interventions for the treatment of depression. It is possible that the efficacy of these treatments will be improved further by the use of adjunctive therapies such as inositol.

Objectives

1. To determine the effectiveness of inositol in the treatment of depression.
2. To determine the adverse effects and acceptability of treatment with inositol.

Search methods

The Cochrane Controlled Trials Register (CCTR), The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR) incorporating results of group searches of EMBASE, MEDLINE, LILACS, CINAHL, PSYNDEX and PsycLIT were searched. Reference lists of relevant papers and major textbooks of affective disorder were checked. Experts in the field and pharmaceutical companies were contacted regarding unpublished material.

Selection criteria

All randomised controlled trials that compare treatment with inositol, whether as monotherapy or adjunctive therapy, to an alternative treatment, whether another antidepressant medication or placebo, for patients with a diagnosis of depressive disorder (diagnosed according to explicit criteria).

Data collection and analysis

Data were independently extracted from the original reports by two reviewers. Statistical analysis was conducted using Review Manager version 4.2.1.

Main results

Four trials were identified, with a total of 141 participants. These were short term trials of double-blind design. The trials did not show clear evidence of a therapeutic benefit, nor any evidence of poor acceptability.

Authors' conclusions

It is currently unclear whether or not inositol is of benefit in the treatment of depression. Ongoing studies should reduce this uncertainty.

摘要

背景

以肌醇(Inositol)治療憂鬱症

憂鬱症的治療有許多有效的介入方式. 這些療法有可能藉由使用輔佐治療, 例如肌醇(Inositol),更進一步提昇其療效

目標

1.判定肌醇(Inositol)在憂鬱症治療的效用 2.判定以肌醇(Inositol)治療的副作用與可接受度

搜尋策略

搜尋Cochrane Controlled Trials Register (CCTR), The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR) 加上團體搜尋EMBASE, MEDLINE, LILACS, CINAHL, PSYNDEX 和 PsycLIT的結果. 我們確認相關論文的參考文獻清單和情感性疾患的參考書. 也接觸此領域的專家和藥廠,討論關於未發表的素材.

選擇標準

所有將肌醇(不管是將肌醇用作單獨治療或是輔佐治療)與其他療法(不管是抗憂鬱劑或安慰劑)做比較的隨機控制試驗, 對象是診斷為憂鬱症的病人(根據外顯的診斷標準)

資料收集與分析

資料由兩位文獻回顧者獨立地從原著擷取. 以Review Manager (版本4.2.1)進行統計分析

主要結論

共找到4篇試驗,總計141位參加者. 這些是短期的雙盲設計試驗. 這些試驗結果並未顯示治療助益的明顯證據,也沒有任何接受度差的證據.

作者結論

究竟肌醇對治療憂鬱症有沒有幫助,目前仍不清楚。持續進行中的研究應該要降低此不確定性.

翻譯人

本摘要由彰化基督教醫院李冠瑩翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

肌醇是一種營養補給品,被建議可以拿來治療憂鬱症。這篇文獻回顧發現究竟肌醇對治療憂鬱症有沒有幫助,目前的證據仍不清楚. 持續進行中的研究應該要降低此不確定性

Plain language summary

Inositol for depression

Inositol is a nutritional supplement that has been suggested as a treatment for depressive disorders. The reviewers found the current evidence is unclear whether or not inositol is of benefit in the treatment of depression. There are ongoing studies that should reduce this uncertainty.

Ancillary